JP2022547452A5 - - Google Patents
Info
- Publication number
- JP2022547452A5 JP2022547452A5 JP2022513902A JP2022513902A JP2022547452A5 JP 2022547452 A5 JP2022547452 A5 JP 2022547452A5 JP 2022513902 A JP2022513902 A JP 2022513902A JP 2022513902 A JP2022513902 A JP 2022513902A JP 2022547452 A5 JP2022547452 A5 JP 2022547452A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- composition according
- antibody
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962895107P | 2019-09-03 | 2019-09-03 | |
| US62/895,107 | 2019-09-03 | ||
| PCT/IB2020/058114 WO2021044287A1 (en) | 2019-09-03 | 2020-09-01 | Treatment of liver disease or disorder comprising actrii receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022547452A JP2022547452A (ja) | 2022-11-14 |
| JP2022547452A5 true JP2022547452A5 (cg-RX-API-DMAC7.html) | 2025-01-15 |
| JP7663559B2 JP7663559B2 (ja) | 2025-04-16 |
Family
ID=72422213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513902A Active JP7663559B2 (ja) | 2019-09-03 | 2020-09-01 | Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220340668A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4025248A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7663559B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220054608A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114630681A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020341135A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022003884A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3153062A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL290852A (cg-RX-API-DMAC7.html) |
| JO (1) | JOP20220057A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022002636A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021044287A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| JP2025529933A (ja) * | 2022-08-26 | 2025-09-09 | バーサニス・バイオ・インコーポレイテッド | ＡｃｔＲＩＩ抗体固定単位用量の治療 |
| CN117577330B (zh) * | 2024-01-15 | 2024-04-02 | 北京大学 | 预测非酒精性脂肪性肝病肝纤维化程度的装置及存储介质 |
| WO2025183966A1 (en) | 2024-02-28 | 2025-09-04 | Versanis Bio, Inc. | Actrii antibodies with extended half life |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050186593A1 (en) | 1991-05-10 | 2005-08-25 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| JP4544742B2 (ja) | 1998-05-06 | 2010-09-15 | メタモーフイクス・インコーポレーテツド | Ｇｄｆ−８の阻害による糖尿病の処置法 |
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| PE20120532A1 (es) * | 2009-04-27 | 2012-05-18 | Novartis Ag | ANTICUERPOS ANTI-ActRIIB |
| AU2010315245B2 (en) * | 2009-11-03 | 2016-11-03 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
| KR101461706B1 (ko) * | 2011-04-04 | 2014-11-18 | 한국생명공학연구원 | Ｄｌｋ１ 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2ｂ 억제제 |
| CN104513213A (zh) | 2013-09-28 | 2015-04-15 | 山东亨利医药科技有限责任公司 | Fxr激动剂 |
| EP3116878A4 (en) | 2014-03-13 | 2018-02-14 | Salk Institute for Biological Studies | Fxr agonists and methods for making and using |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| CN111662297A (zh) | 2014-11-21 | 2020-09-15 | 阿卡纳治疗学有限公司 | 用于治疗疾病的稠合双环化合物 |
| EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| WO2016103037A1 (en) | 2014-12-22 | 2016-06-30 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| WO2017078928A1 (en) | 2015-11-06 | 2017-05-11 | Salk Institute For Biological Studies | Fxr agonists and methods for making and using |
| CN106946867B (zh) | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
| WO2017128896A1 (zh) | 2016-01-26 | 2017-08-03 | 江苏豪森药业集团有限公司 | Fxr激动剂及其制备方法和应用 |
| WO2017143134A1 (en) | 2016-02-19 | 2017-08-24 | Alios Biopharma, Inc. | Fxr modulators and methods of their use |
| US20170240639A1 (en) | 2016-02-22 | 2017-08-24 | Acceleron Pharma Inc. | Actrii antagonists for use in increasing immune activity |
| WO2017189651A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| WO2017201155A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
| US10183872B2 (en) | 2016-06-13 | 2019-01-22 | Qi Wang | Counter circulating liquid processing system by repeatedly re-using thermal energy |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| US11091482B2 (en) | 2016-08-23 | 2021-08-17 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators |
| CN108430998B (zh) | 2016-09-28 | 2021-07-09 | 四川科伦博泰生物医药股份有限公司 | 氮杂双环衍生物及其制备方法和用途 |
| MX2019003790A (es) | 2016-10-04 | 2019-09-26 | Enanta Pharm Inc | Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos. |
| CN107973790A (zh) | 2016-10-22 | 2018-05-01 | 合帕吉恩治疗公司 | 杂环fxr调节剂 |
| WO2018081285A1 (en) | 2016-10-26 | 2018-05-03 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof |
| CN108017636A (zh) | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| CN109071468B (zh) | 2017-01-20 | 2022-09-02 | 四川科伦博泰生物医药股份有限公司 | 一种杂环化合物及其制备方法和用途 |
| WO2018190643A1 (en) | 2017-04-12 | 2018-10-18 | Il Dong Pharmaceutical Co., Ltd. | An isoxazole derivatives as nuclear receptor agonists and used thereof |
| US11339147B2 (en) | 2017-05-26 | 2022-05-24 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Lactam compound as FXR receptor agonist |
| KR102400183B1 (ko) | 2017-07-06 | 2022-05-18 | 수안주 바이오파마슈티컬 컴퍼니 리미티드 | Fxr 작용제 |
| CN109053751A (zh) | 2018-08-30 | 2018-12-21 | 成都海博锐药业有限公司 | 具有螺环结构的fxr调节剂 |
-
2020
- 2020-09-01 CA CA3153062A patent/CA3153062A1/en active Pending
- 2020-09-01 WO PCT/IB2020/058114 patent/WO2021044287A1/en not_active Ceased
- 2020-09-01 US US17/639,862 patent/US20220340668A1/en active Pending
- 2020-09-01 EP EP20768112.3A patent/EP4025248A1/en active Pending
- 2020-09-01 MX MX2022002636A patent/MX2022002636A/es unknown
- 2020-09-01 AU AU2020341135A patent/AU2020341135A1/en active Pending
- 2020-09-01 KR KR1020227007746A patent/KR20220054608A/ko active Pending
- 2020-09-01 BR BR112022003884A patent/BR112022003884A2/pt unknown
- 2020-09-01 CN CN202080062007.XA patent/CN114630681A/zh active Pending
- 2020-09-01 JP JP2022513902A patent/JP7663559B2/ja active Active
-
2022
- 2022-02-23 IL IL290852A patent/IL290852A/en unknown
- 2022-03-02 JO JOP/2022/0057A patent/JOP20220057A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022547452A5 (cg-RX-API-DMAC7.html) | ||
| JP7266530B2 (ja) | エラフィブラノールのようなＰＰＡＲアゴニスト及びアセチルＣｏＡカルボキシラーゼ（ＡＣＣ）を含む組合せ | |
| TW202323296A (zh) | 組合療法 | |
| WO2023280152A1 (en) | Combination therapy for treatment of liver diseases | |
| AU2020203316B2 (en) | Novel regimes of FXR agonists | |
| JP7175897B2 (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| RU2471483C2 (ru) | Противоопухолевые комбинации, содержащие ингибитор vegf и иринотекан | |
| CN115461072A (zh) | 用于治疗非酒精性脂肪性肝炎的司美格鲁肽 | |
| JP2021513552A5 (cg-RX-API-DMAC7.html) | ||
| AU2020201980A1 (en) | Combination of FXR agonists | |
| JP2023507364A (ja) | インテグリン阻害剤を使用する肝疾患の治療の組み合わせ | |
| JP2022549066A5 (cg-RX-API-DMAC7.html) | ||
| JP2025508852A (ja) | 環状ホスホネート組成物およびその調製方法 | |
| JP2021529766A5 (cg-RX-API-DMAC7.html) | ||
| CN117915914A (zh) | 治疗肝病的组合疗法 | |
| CA3100635A1 (en) | Combinations comprising tropifexor and cenicriviroc | |
| JP2022522873A5 (cg-RX-API-DMAC7.html) | ||
| US12559553B2 (en) | IL-31 modulators for treating FXR-induced pruritus | |
| RU2022104049A (ru) | Комбинированное лечение заболеваний печени агонистами fxr | |
| Sumida et al. | An eBook on Diabetes | |
| JP2023522907A (ja) | 抗ｃｃｌ２４抗体を使用する処置方法 | |
| Prous | Annual Update 2004/2005-Treatment of gastrointestinal disorders | |
| Martin et al. | Pemphigus |